Jun 2026 (Q2 FY26) — Aug 3, 2026
Jazz Pharmaceuticals Q2 FY26 — Record Revenue and Raised Full-Year Guidance
Read the full callJazz Pharmaceuticals (JAZZ) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Jazz Pharmaceuticals earnings: last reported Mon, 3 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 1,208 | +15.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 20.5 | +86.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 193 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$208.43 −0.86% · −$1.8
Performance +53.2% 1Y
1Y: $136.06 on 17 Oct 2025 → $208.43. High $261.62 (4 Aug 2026), low $131.16 (7 Nov 2025).
- Previous close
- $210.23
- 52-week range
- $131.16 – $261.62
- One year
- +54.56%
Overview
- Symbol
- JAZZ
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
Jazz Pharmaceuticals Q1 FY26 — Record Revenue and Zanidatamab Progress Drive Strong Start
Read the full callDec 2025 (Q4 FY25) — Feb 24, 2026
Jazz Pharmaceuticals Q4 FY25 — Record Revenue and Strategic Focus on Rare Disease
Read the full callEvery analysed call
Jazz Pharmaceuticals earnings calls (JAZZ)
Financials
What the filings say
Net profit, year on year: +127% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,055 | 1,088 | 898 | 1,046 | 1,126 | 1,198 | 1,069 | 1,208 |
| Expenses | 795 | 897 | 954 | 1,732 | 1,069 | 943 | 732 | 960 |
| Operating profit | 260 | 191 | -56 | -686 | 58 | 255 | 337 | 248 |
| Operating margin | 24.7% | 17.5% | −6.2% | −65.6% | 5.1% | 21.3% | 31.5% | 20.5% |
| Profit before tax | 201 | 133 | -110 | -736 | 9 | 208 | 299 | 211 |
| Tax rate | −7.2% | −43.5% | 16.2% | 2.3% | −2683.2% | 2.4% | 2.0% | 8.6% |
| Net profit | 215 | 191 | -92 | -718 | 251 | 203 | 293 | 193 |
| EPS ($ per share) | 3.50 | — | -1.52 | -11.74 | 4.14 | — | 4.73 | 3.05 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 841 | 1,068 | 1,160 | 830 | 734 | 879 | 1,127 | 646 |
| Total liabilities | 2,446 | 2,428 | 2,876 | 8,333 | 7,750 | 7,656 | 7,919 | 7,341 |
| Fixed assets | 200 | 132 | 128 | 257 | 228 | 170 | 173 | 200 |
| Total assets | 5,203 | 5,539 | 6,536 | 12,299 | 10,835 | 11,393 | 12,012 | 11,659 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 799 | 776 | 900 | 779 | 1,272 | 1,092 | 1,396 | 1,356 |
| Cash from investing | -394 | -155 | -1,008 | -5,212 | -446 | -163 | -508 | -1,510 |
| Cash from financing | -479 | -294 | 528 | 3,971 | -529 | -305 | 21 | -873 |
| Net cash flow | -76 | 328 | 420 | -466 | 290 | 625 | 907 | -1,021 |
| Capital expenditure | -20 | -40 | -15 | -28 | -29 | -24 | -38 | -59 |
| Free cash flow | 779 | 736 | 885 | 751 | 1,243 | 1,068 | 1,358 | 1,297 |
JAZZ revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Sleep | — | — | — | — | — | — | 41% | 42% | — |
| Xywav | 37% | 37% | 38% | 40% | 38% | 39% | 38% | 39% | +13.5% |
| Oncology | — | — | — | — | — | — | 31% | 30% | — |
| Epilepsy | — | — | — | — | — | — | 23% | 24% | — |
| Epidiolex Epidyolex | 24% | 25% | 24% | 24% | 27% | 24% | 23% | 24% | +16.0% |
| Zepzelca | 8% | 7% | 7% | 7% | 7% | 8% | 9% | 9% | +41.9% |
| Rylaze Enrylaze | 9% | 9% | 11% | 10% | 9% | 9% | 10% | 8% | -1.2% |
| Defitelio Defibrotide | 6% | 5% | 5% | 5% | 5% | 5% | 4% | 5% | +28.9% |
| Product and Services Royalties and Contract Revenue | 6% | 6% | 7% | 6% | 5% | 5% | 4% | 4% | -13.2% |
| Modeyso | — | — | — | — | 1% | — | 4% | 4% | — |
| High Sodium AG Oxybate Product Royalty Revenue | 6% | 5% | 5% | 5% | 5% | 5% | 3% | 3% | -22.1% |
| Vyxeos | 3% | 5% | 3% | 4% | 3% | 3% | 2% | 3% | -30.0% |
| Xyrem | 6% | 5% | 4% | 3% | 3% | 3% | 3% | 3% | -13.7% |
| Ziihera | — | — | <1% | 1% | 1% | 1% | 1% | 1% | +157.1% |
| Other Royalty and Contract Revenues | 1% | — | 1% | 1% | 1% | — | 1% | 1% | +66.6% |
| Other Products | <1% | <1% | 1% | <1% | <1% | <1% | <1% | 0% | -100.0% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 89% ↓ 1 pt
- Europe 8% ↑ 1 pt
- Other Countries 3%
As JAZZ cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
151 filings between Nov 17, 2025 and Oct 6, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$69.82M
59 sales by 11 insiders
42% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 27
- Award — granted as compensation
- 17
- Option exercise — converted options into shares
- 45
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 dispositions to the issuer, 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| COZADD BRUCE C | — | $27.78M | Oct 1, 2026 |
| Iannone Robert | — | $20.41M | Aug 27, 2026 |
| Patil Neena M | — | $11.50M | Sep 10, 2026 |
| Carr Patricia | — | $2.46M | Mar 9, 2026 |
| Winningham Rick E | — | $1.66M | May 22, 2026 |
| Pearce Samantha | — | $1.63M | May 28, 2026 |
| Henderson Mary Elizabeth | — | $1.42M | Feb 26, 2026 |
| McSharry Heather Ann | — | $1.09M | May 22, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 6, 2026 | GALA RENEE D President & CEO | Sale 10b5-1 plan | 2,000 | $472.8K |
| Oct 1, 2026 | COZADD BRUCE C Director | Sale 10b5-1 plan | 6,000 | $1.38M |
| Sep 10, 2026 | Patil Neena M EVP & Chief Legal Officer | Sale 10b5-1 plan | 1,200 | $289.1K |
| Sep 8, 2026 | Henderson Mary Elizabeth SVP, Technical Operations | Tax withheld | 15 | $3.6K |
| Sep 8, 2026 | Henderson Mary Elizabeth SVP, Technical Operations | Tax withheld | 1,412 | $343.2K |
| Sep 8, 2026 | GALA RENEE D President & CEO | Sale 10b5-1 plan | 2,000 | $486.1K |
| Sep 8, 2026 | GALA RENEE D President & CEO | Tax withheld 10b5-1 plan | 1,967 | $485.5K |
| Sep 1, 2026 | COZADD BRUCE C Director | Sale 10b5-1 plan | 6,000 | $1.50M |
| Aug 31, 2026 | Henderson Mary Elizabeth SVP, Technical Operations | Tax withheld | 16 | $3.9K |
| Aug 31, 2026 | RIEDEL NORBERT G Director | Tax withheld | 1,692 | $408.4K |
| Aug 31, 2026 | RIEDEL NORBERT G Director | Tax withheld | 14 | $3.4K |
| Aug 31, 2026 | ENRIGHT PATRICK G Director | Tax withheld | 1,692 | $408.4K |
| Aug 31, 2026 | Hamill Laura Director | Tax withheld | 1,692 | $408.4K |
| Aug 31, 2026 | Winningham Rick E Director | Tax withheld | 1,692 | $408.4K |
| Aug 31, 2026 | McSharry Heather Ann Director | Tax withheld | 1,840 | $444.2K |
| Aug 31, 2026 | COZADD BRUCE C Director | Tax withheld 10b5-1 plan | 10 | $2.4K |
| Aug 31, 2026 | ENRIGHT PATRICK G Director | Tax withheld | 14 | $3.4K |
| Aug 31, 2026 | Cook Jennifer E. Director | Tax withheld | 14 | $3.4K |
| Aug 31, 2026 | Hamill Laura Director | Tax withheld | 14 | $3.4K |
| Aug 31, 2026 | LOVE TED W Director | Tax withheld | 6 | $1.5K |
| Aug 31, 2026 | McSharry Heather Ann Director | Tax withheld | 15 | $3.7K |
| Aug 31, 2026 | LOVE TED W Director | Tax withheld | 737 | $177.9K |
| Aug 31, 2026 | Winningham Rick E Director | Tax withheld | 14 | $3.4K |
| Aug 31, 2026 | COZADD BRUCE C Director | Tax withheld 10b5-1 plan | 1,209 | $291.8K |
| Aug 31, 2026 | Kennedy Patrick Director | Tax withheld | 1,840 | $444.2K |
| Aug 31, 2026 | Kennedy Patrick Director | Tax withheld | 15 | $3.7K |
| Aug 31, 2026 | Cook Jennifer E. Director | Tax withheld | 1,692 | $408.4K |
| Aug 31, 2026 | Smith Mark Douglas Director | Tax withheld | 1,692 | $408.4K |
| Aug 31, 2026 | Smith Mark Douglas Director | Tax withheld | 14 | $3.4K |
| Aug 31, 2026 | Henderson Mary Elizabeth SVP, Technical Operations | Tax withheld | 2,076 | $501.1K |
| Aug 27, 2026 | Iannone Robert EVP, Global Head of R&D & CMO | Option exercise 10b5-1 plan | 26,116 | $2.95M |
| Aug 27, 2026 | Iannone Robert EVP, Global Head of R&D & CMO | Option exercise 10b5-1 plan | 884 | $100.0K |
| Aug 27, 2026 | Iannone Robert EVP, Global Head of R&D & CMO | Option exercise 10b5-1 plan | 2,916 | $399.8K |
| Aug 27, 2026 | Iannone Robert EVP, Global Head of R&D & CMO | Option exercise 10b5-1 plan | 27,584 | $3.78M |
| Aug 27, 2026 | Iannone Robert EVP, Global Head of R&D & CMO | Sale 10b5-1 plan | 18,187 | $4.51M |
| Aug 27, 2026 | Iannone Robert EVP, Global Head of R&D & CMO | Sale 10b5-1 plan | 300 | $75.8K |
| Aug 27, 2026 | Iannone Robert EVP, Global Head of R&D & CMO | Sale 10b5-1 plan | 11,423 | $2.84M |
| Aug 27, 2026 | Iannone Robert EVP, Global Head of R&D & CMO | Sale 10b5-1 plan | 18,113 | $4.53M |
| Aug 27, 2026 | Iannone Robert EVP, Global Head of R&D & CMO | Sale 10b5-1 plan | 19,639 | $4.92M |
| Aug 27, 2026 | Iannone Robert EVP, Global Head of R&D & CMO | Sale 10b5-1 plan | 9,259 | $2.33M |
| Aug 5, 2026 | RIEDEL NORBERT G Director | Award | 1,605 | $0 |
| Aug 5, 2026 | McSharry Heather Ann Director | Award | 1,605 | $0 |
| Aug 5, 2026 | Mulligan Seamus Director | Award | 1,605 | $0 |
| Aug 5, 2026 | COZADD BRUCE C Director | Award | 1,605 | $0 |
| Aug 5, 2026 | Kennedy Patrick Director | Award | 1,605 | $0 |
| Aug 5, 2026 | Pearce Samantha EVP, Chief Commercial Officer | Tax withheld | 780 | $204.1K |
| Aug 5, 2026 | Winningham Rick E Director | Award | 1,605 | $0 |
| Aug 5, 2026 | Smith Mark Douglas Director | Award | 1,605 | $0 |
| Aug 5, 2026 | Cook Jennifer E. Director | Award | 1,605 | $0 |
| Aug 5, 2026 | ENRIGHT PATRICK G Director | Award | 1,605 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Jazz Pharmaceuticals plc
Free account. Everything above stays public.
Write why you follow Jazz Pharmaceuticals plc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading